A retrospective study assessing clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery
Latest Information Update: 22 Sep 2021
At a glance
- Drugs Dexamethasone (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms dexcat
Most Recent Events
- 22 Sep 2021 New trial record
- 01 Feb 2021 Primary endpoint (Anatomical and functional results at 3 months) has been met according to the results published in the Acta Ophthalmologica